Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
type
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1753523

	registered interest
	date	08/01/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of restrictions on the use of electronic prescriptions for the issuing of medicinal cannabis products.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	type	WrittenParliamentaryQuestion
	uin	22612
	answer	answer is ministerial correction date of answer 13/01/2025 answer text <p>Rules around the electronic prescribing of cannabis-based medicines are no different to other drugs regulated in Schedule 2 to 5 of the Misuse of Drugs Regulations 2001.</p><p>In England, the NHS Electronic Prescription Service (EPS) enables the electronic transmission of prescriptions for Schedule 2 to 5 controlled drugs. As part of the robust system of governance and restrictions around the most addictive and harmful drugs, all private healthcare provider prescriptions for Schedule 2 and 3 controlled drugs cannot be transmitted by electronic means and must be issued on a paper FP10PCD prescription form. All paper copies of private prescriptions of Schedule 2 and 3 controlled drugs must be submitted to the NHS Business Services Authority. NHS England Controlled Drug Accountable Officers have a statutory duty to monitor the management and use of controlled drugs in the National Health Service and private healthcare.</p><p>Similar legislative and governance arrangements are in place in Northern Ireland concerning the management and use of controlled drugs. All private prescribing of Schedule 2 and 3 controlled drugs must be issued on a paper PCD1 prescription form, which, once dispensed, are submitted to the Business Services Organisation, in line with requirements in the Misuse of Drugs (Northern Ireland) Regulations 2002. There is currently no electronic transmission of prescriptions in primary care in Northern Ireland.</p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) does not provide guidance on the use of medicinal cannabis. The MHRA provides guidance on manufacturing, importing, distributing, and supplying unlicensed medicines, which includes cannabis-based products for medicinal use in humans.</p><p>Current guidelines on the prescribing and use of cannabis-based medicinal products, specifically guideline NG144, are published on the National Institute for Health and Care Excellence website, which is available at the following link:</p><p><a href="https://www.nice.org.uk/" target="_blank">https://www.nice.org.uk/</a></p><p>The guidelines have been endorsed by the Department of Health in Northern Ireland as applicable within Health and Social Care in Northern Ireland. The National Institute for Health and Care Excellence develops its guidance independently and keeps its published guidelines under active surveillance, so that it is able to update its recommendations in light of any significant new evidence.</p> answering member constituency Bristol South answering member printed Karin Smyth grouped question UIN 22614 question first answered 13/01/2025 15:40:06 answering member 4444 label Biography information for Karin Smyth
	tabling member	4131 label Biography information for Jim Shannon

1753525

	registered interest
	date	08/01/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cannabis: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of the Medicines and Healthcare products Regulatory Agency guidance on the use of medicinal cannabis.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	type	WrittenParliamentaryQuestion
	uin	22614
	answer	answer is ministerial correction date of answer 13/01/2025 answer text <p>Rules around the electronic prescribing of cannabis-based medicines are no different to other drugs regulated in Schedule 2 to 5 of the Misuse of Drugs Regulations 2001.</p><p>In England, the NHS Electronic Prescription Service (EPS) enables the electronic transmission of prescriptions for Schedule 2 to 5 controlled drugs. As part of the robust system of governance and restrictions around the most addictive and harmful drugs, all private healthcare provider prescriptions for Schedule 2 and 3 controlled drugs cannot be transmitted by electronic means and must be issued on a paper FP10PCD prescription form. All paper copies of private prescriptions of Schedule 2 and 3 controlled drugs must be submitted to the NHS Business Services Authority. NHS England Controlled Drug Accountable Officers have a statutory duty to monitor the management and use of controlled drugs in the National Health Service and private healthcare.</p><p>Similar legislative and governance arrangements are in place in Northern Ireland concerning the management and use of controlled drugs. All private prescribing of Schedule 2 and 3 controlled drugs must be issued on a paper PCD1 prescription form, which, once dispensed, are submitted to the Business Services Organisation, in line with requirements in the Misuse of Drugs (Northern Ireland) Regulations 2002. There is currently no electronic transmission of prescriptions in primary care in Northern Ireland.</p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) does not provide guidance on the use of medicinal cannabis. The MHRA provides guidance on manufacturing, importing, distributing, and supplying unlicensed medicines, which includes cannabis-based products for medicinal use in humans.</p><p>Current guidelines on the prescribing and use of cannabis-based medicinal products, specifically guideline NG144, are published on the National Institute for Health and Care Excellence website, which is available at the following link:</p><p><a href="https://www.nice.org.uk/" target="_blank">https://www.nice.org.uk/</a></p><p>The guidelines have been endorsed by the Department of Health in Northern Ireland as applicable within Health and Social Care in Northern Ireland. The National Institute for Health and Care Excellence develops its guidance independently and keeps its published guidelines under active surveillance, so that it is able to update its recommendations in light of any significant new evidence.</p> answering member constituency Bristol South answering member printed Karin Smyth grouped question UIN 22612 question first answered 13/01/2025 15:40:06 answering member 4444 label Biography information for Karin Smyth
	tabling member	4131 label Biography information for Jim Shannon

1753537

	registered interest
	date	08/01/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Sepsis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many people in the UK have been diagnosed with sepsis in the last 12 months.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	type	WrittenParliamentaryQuestion
	uin	22615
	answer	answer is ministerial correction date of answer 13/01/2025 answer text <p>There is a lack of reliable estimates of the incidence and prevalence of sepsis, due to the inconsistency in the definitions used to describe sepsis, and the differences in coding between professionals and organisations in the United Kingdom.</p><p>The Office for National Statistics (ONS) publishes data on the number of death registrations where sepsis was the underlying cause of death, and where sepsis was mentioned anywhere on the death certificate, for England and Wales between 2001 and 2023. According to the ONS, in 2023, the number of deaths registered where sepsis was mentioned anywhere on the death certificate in England and Wales was 26,203. The ONS has not yet published the number of death registrations for sepsis for 2024. The published ONS data for deaths involving sepsis is available at the following link:</p><p><a href="https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/2111deathsinvolvingsepsisenglandandwales2001to2023" target="_blank">https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/2111deathsinvolvingsepsisenglandandwales2001to2023</a></p><p>The Department continues to work with NHS England and the UK Health Security Agency to improve our understanding of sepsis data and to monitor trends in infection incidence and deaths from sepsis, which are complex and multifactorial.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 13/01/2025 14:59:45 answering member 1506 label Biography information for Andrew Gwynne
	tabling member	4131 label Biography information for Jim Shannon

1753540

	registered interest
	date	08/01/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Brain: Tumours
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will take steps to prioritise screening for brain tumours.
	tabling member constituency	Runcorn and Helsby
	tabling member printed	Mike Amesbury
	type	WrittenParliamentaryQuestion
	uin	22668
	answer	answer is ministerial correction date of answer 13/01/2025 answer text <p>In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee, an independent scientific advisory committee which advises Ministers and the National Health Service in all four countries on all aspects of population and targeted screening and supports implementation.</p><p>The UK National Screening Committee has not been asked to look at screening for brain tumours. The Committee welcomes any new published peer reviewed evidence which suggests the case for a new or modified screening programme via its annual call, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/uk-nsc-annual-call-submitting-a-screening-proposal/uk-nsc-annual-call-how-to-submit-a-proposal" target="_blank">https://www.gov.uk/government/publications/uk-nsc-annual-call-submitting-a-screening-proposal/uk-nsc-annual-call-how-to-submit-a-proposal</a></p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 13/01/2025 10:30:25 answering member 1506 label Biography information for Andrew Gwynne
	tabling member	4667 label Biography information for Mike Amesbury

1753541

	registered interest
	date	08/01/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when the new Neffy treatment for severe allergic reactions will be available on the NHS.
	tabling member constituency	Rutland and Stamford
	tabling member printed	Alicia Kearns
	type	WrittenParliamentaryQuestion
	uin	22696
	answer	answer is ministerial correction date of answer 14/01/2025 answer text <p>It is critical that medicines used in the United Kingdom are safe and effective. The Medicines and Healthcare products Regulatory Agency (MHRA) assesses all medicines before they can be used in the UK. Neffy (epinephrine nasal spray) has not been licenced by the MHRA. Should an application for it be received, the MHRA will consider the benefit-risk of the product accordingly in regards to its quality, safety and effectiveness. It is the responsibility of the company to apply to the MHRA for a marketing authorisation.</p><p> </p><p>Local National Health Service organisations are expected to make decisions on the availability of medicines based on an assessment of the available evidence and taking into account any relevant national guidance.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 14/01/2025 10:10:37 answering member 4444 label Biography information for Karin Smyth
	tabling member	4805 label Biography information for Alicia Kearns

1753543

	registered interest
	date	08/01/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prostate Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of a national screening programme for prostate cancer.
	tabling member constituency	Runcorn and Helsby
	tabling member printed	Mike Amesbury
	type	WrittenParliamentaryQuestion
	uin	22669
	answer	answer is ministerial correction date of answer 13/01/2025 answer text <p>Screening for prostate cancer is currently not recommended in the United Kingdom, due to the inaccuracy of the current best test Prostate Specific Antigen.</p><p>A UK National Screening Committee (UK NSC) review looking at whether to offer screening for prostate cancer is currently underway. This evidence review will cover modelling the clinical effectiveness and cost of several approaches to prostate cancer screening. This will include different potential ways of screening the whole population and targeted screening aimed at groups of people identified as being at higher-than-average risk, such as Black men or men with a family history of cancer.</p><p>Once the modelling and evidence review is complete, it will be considered by the UK NSC. Subject to no further revisions being required, the UK NSC plans to look at the findings towards the end of 2025.</p><p>Further details of the UK NSC’s evidence review process are available at the following link:</p><p><a href="https://www.gov.uk/government/publications/uk-nsc-evidence-review-process/uk-nsc-evidence-review-process" target="_blank">https://www.gov.uk/government/publications/uk-nsc-evidence-review-process/uk-nsc-evidence-review-process</a></p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 13/01/2025 10:35:04 answering member 1506 label Biography information for Andrew Gwynne
	tabling member	4667 label Biography information for Mike Amesbury

1753544

	registered interest
	date	08/01/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ambulance Services: Standards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of ambulance waiting times over the 2024-25 Christmas and new year period.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	type	WrittenParliamentaryQuestion
	uin	22616
	answer	answer is ministerial correction date of answer 14/01/2025 answer text <p>Ambulance response times have been below the high standards that patients should expect in recent years. The Government has committed to supporting the National Health Service to improve performance and achieve the standards set out in the NHS Constitution, including ambulance response times.</p><p>The following table shows the national ambulance response time performance in December 2024 for Category 1, 2, 3 and 4 incidents, in hours, minutes and seconds:</p><table><tbody><tr><td><p>Category of incident</p></td><td><p>December 2024 national average</p></td><td><p>NHS constitution standard</p></td></tr><tr><td><p>Category 1 – average response time</p></td><td><p>00:08:40</p></td><td><p>00:07:00</p></td></tr><tr><td><p>Category 1 – 90<sup>th</sup> centile response time</p></td><td><p>00:15:25</p></td><td><p>00:15:00</p></td></tr><tr><td><p>Category 2 – average response time</p></td><td><p>00:47:26</p></td><td><p>00:18:00</p></td></tr><tr><td><p>Category 2 – 90<sup>th</sup> centile response time</p></td><td><p>01:41:40</p></td><td><p>00:40:00</p></td></tr><tr><td><p>Category 3 – 90<sup>th</sup> centile response time</p></td><td><p>07:21:03</p></td><td><p>02:00:00</p></td></tr><tr><td><p>Category 4 – 90<sup>th</sup> centile response time</p></td><td><p>08:15:44</p></td><td><p>03:00:00</p></td></tr></tbody></table><p>Source: NHS England Ambulance Quality Indicators (<a href="https://www.england.nhs.uk/statistics/statistical-work-areas/ambulance-quality-indicators/" target="_blank">https://www.england.nhs.uk/statistics/statistical-work-areas/ambulance-quality-indicators/</a>)</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 14/01/2025 09:17:43 answering member 4444 label Biography information for Karin Smyth
	tabling member	4131 label Biography information for Jim Shannon

1753545

	registered interest
	date	08/01/2025
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Dementia
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of trends in levels of people diagnosed with dementia over the last five years.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	type	WrittenParliamentaryQuestion
	uin	22617
	answer	answer is ministerial correction date of answer 14/01/2025 answer text <p>The national target is for 66.7% of people estimated to be living with dementia to receive a formal diagnosis. The latest dementia diagnosis rate reported by NHS England for the end of November 2024 was 65.8%.</p><p>The target had been met consistently at the national level from July 2016 until end of March 2020, when it dropped due to the COVID-19 pandemic, as memory services were reduced in capacity and general practitioner referrals into these services decreased significantly. At a national level, the dementia diagnosis rate is now gradually recovering due to sustained efforts.</p><p>NHS England continue to monitor the monthly dementia diagnosis rate and analyse trends at national, regional, and integrated commissioning board (ICB) level.  This provides a clear direction for ICBs to support delivery of timely diagnoses within local systems and enable access to appropriate post diagnostic support.</p> answering member constituency Aberafan Maesteg answering member printed Stephen Kinnock question first answered 14/01/2025 09:17:37 answering member 4359 label Biography information for Stephen Kinnock
	tabling member	4131 label Biography information for Jim Shannon

1753549

	registered interest
	date	08/01/2025
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Electric Vehicles: Batteries
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Environment, Food and Rural Affairs, whether he plans to reduce the timeframe for the authorisation of new electric vehicle battery recycling facilities.
	tabling member constituency	Twickenham
	tabling member printed	Munira Wilson
	type	WrittenParliamentaryQuestion
	uin	22680
	answer	answer is ministerial correction date of answer 13/01/2025 answer text <p>Environmental permits enable Government missions on economic growth, green innovation and net zero. To protect the environment and the public, all environmental permits require appropriate assessment to prevent harm.</p><p> </p><p>All environmental permitting is subject to statutory timeframes. Defra and the Environment Agency are constantly reviewing and improving Environmental Permitting services to make them efficient and reactive to customer needs. The Environment Agency will consider prioritising applications, if they meet specific criteria that include supporting economic growth or are for nationally significant infrastructure projects.</p><p> </p><p>The Environment Agency encourages applicants to contact them as early as possible in any project plans and take up pre application advice (<a href="https://www.gov.uk/guidance/get-advice-before-you-apply-for-an-environmental-permit" target="_blank">Get advice before you apply for an environmental permit</a>), particularly for complex permits for new and novel technologies such as vehicle battery recycling facilities.</p> answering member constituency Coventry East answering member printed Mary Creagh question first answered 13/01/2025 15:40:34 answering member 1579 label Biography information for Mary Creagh
	tabling member	4776 label Biography information for Munira Wilson

1753553

	registered interest
	date	08/01/2025
	answering body	Ministry of Defence
	answering dept id	11
	answering dept short name	Defence
	answering dept sort name	Defence
	hansard heading	Armed Forces: Rehabilitation
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Defence, how many injured service personal required rehabilitation services in each armed service in each year since 2015; and how much his Department on rehabilitation of injured service personnel in each service in the same period.
	tabling member constituency	Widnes and Halewood
	tabling member printed	Derek Twigg
	type	WrittenParliamentaryQuestion
	uin	22577
	answer	answer is ministerial correction date of answer 13/01/2025 answer text <p>The table below presents the number of UK Armed Forces personnel who have had at least one appointment at Primary Care Rehabilitation Facilities (PCRF), Regional Rehabilitation Units (RRU) and/or Defence Medical Rehabilitation Centre (DMRC) in each year since 2015, broken down by service.</p><p> </p><table><tbody><tr><td><p><strong>Year</strong></p></td><td><p><strong>Total</strong></p></td><td><p><strong>Navy</strong></p></td><td><p><strong>Army</strong></p></td><td><p><strong>RAF</strong></p></td></tr><tr><td><p>2015</p></td><td><p>58,144</p></td><td><p>9,450</p></td><td><p>36,807</p></td><td><p>11,824</p></td></tr><tr><td><p>2016</p></td><td><p>57,332</p></td><td><p>9,348</p></td><td><p>36,053</p></td><td><p>11,847</p></td></tr><tr><td><p>2017</p></td><td><p>55,605</p></td><td><p>9,523</p></td><td><p>34,653</p></td><td><p>11,346</p></td></tr><tr><td><p>2018</p></td><td><p>53,318</p></td><td><p>9,371</p></td><td><p>32,641</p></td><td><p>11,229</p></td></tr><tr><td><p>2019</p></td><td><p>52,981</p></td><td><p>9,678</p></td><td><p>31,775</p></td><td><p>11,446</p></td></tr><tr><td><p>2020</p></td><td><p>42,138</p></td><td><p>7,905</p></td><td><p>25,200</p></td><td><p>8,959</p></td></tr><tr><td><p>2021</p></td><td><p>45,526</p></td><td><p>8,640</p></td><td><p>27,524</p></td><td><p>9,281</p></td></tr><tr><td><p>2022</p></td><td><p>46,673</p></td><td><p>8,959</p></td><td><p>27,920</p></td><td><p>9,739</p></td></tr><tr><td><p>2023</p></td><td><p>45,137</p></td><td><p>8,696</p></td><td><p>26,828</p></td><td><p>9,572</p></td></tr><tr><td><p>2024</p></td><td><p>45,217</p></td><td><p>8,547</p></td><td><p>27,203</p></td><td><p>9,410</p></td></tr></tbody></table><p> </p><p>The table below presents the total spent on rehabilitation at Regional Rehabilitation Units (RRUs), Defence Primary Health Care Rehab Headquarters and the Defence Medical Rehabilitation Centre (DMRC) from the start of 2015 to 8 January 2025.The figures below do not include costs for Primary Care Rehab Facilities (PCRFs). PCRFs provide primary rehabilitation for Service Personnel who do not require referral into an RRU. PCRFs costs are embedded within Medical Centres and the costs cannot be extracted.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p> </p><p>As rehabilitation is delivered in a tri-service environment, it is not possible to break this data down by Service.</p><p> </p><table><tbody><tr><td><p><strong>Financial Year</strong></p></td><td><p><strong>Total </strong><strong>£</strong></p></td></tr><tr><td><p>2015-16</p></td><td><p>28,391,515</p></td></tr><tr><td><p>2016-17</p></td><td><p>22,895,461</p></td></tr><tr><td><p>2017-18</p></td><td><p>27,841,573</p></td></tr><tr><td><p>2018-19</p></td><td><p>31,852,392</p></td></tr><tr><td><p>2019-20</p></td><td><p>40,041,538</p></td></tr><tr><td><p>2020-21</p></td><td><p>32,473,582</p></td></tr><tr><td><p>2021-22</p></td><td><p>35,275,941</p></td></tr><tr><td><p>2022-23</p></td><td><p>39,037,736</p></td></tr><tr><td><p>2023-24</p></td><td><p>41,468,534</p></td></tr><tr><td><p>2024-25</p></td><td><p>30,885,020</p></td></tr><tr><td><p><strong>Total</strong></p></td><td><p><strong>332,536,267</strong></p></td></tr></tbody></table><p> </p> answering member constituency Birmingham Selly Oak answering member printed Al Carns question first answered 13/01/2025 16:38:56 answering member 5235
	tabling member	429 label Biography information for Derek Twigg